Receptor News and Research

RSS

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins. The structure should help instruct the design of a new kind of therapeutics for conditions ranging from Parkinson's disease to inflammation.

11 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Despite aspirin therapy, specific inflammatory pathways may influence risk of colorectal cancer

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Swine flu virus may evolve into a deadlier form

In the fall of 1917, a new strain of influenza swirled around the globe. At first, it resembled a typical flu epidemic: Most deaths occurred among the elderly, while younger people recovered quickly. However, in the summer of 1918, a deadlier version of the same virus began spreading, with disastrous consequence. In total, the pandemic killed at least 50 million people - about 3 percent of the world's population at the time.

10 Mar 2011

Blood biomarker may help decide intake of aspirin or NSAIDs for reduction of cancer risk

The reduced risk of colorectal cancer associated with taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may be confined to individuals already at risk because of elevations in a particular inflammatory factor in the blood.

10 Mar 2011

Immunologists identify key cell component that triggers allergic responses to cat dander

A breakthrough by scientists at The University of Nottingham could provide hope for any allergy sufferers who have ever had to choose between their health and their household pet.

10 Mar 2011

Study supports DNA mismatch repair test for bowel cancer

Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumour recurrence post surgery, results from a major clinical study have demonstrated.

9 Mar 2011

Multiple target therapy may treat HER2-positive breast cancers

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center investigators.

9 Mar 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

Researchers elucidate how sensory, motor fibers interact at molecular level to form nerves

During embryonic development, sensory and motor fibers interact to form nerves in the limbs. The research team led by Dr. Andrea Huber Br-samle of the Institute of Developmental Genetics of Helmholtz Zentrum M-nchen has now elucidated how this interaction functions at the molecular level: The cell surface receptor neuropilin-1 is present in both sensory and motor nerve fibers and controls their interaction in order to correctly regulate growth.

8 Mar 2011

URMC research confirms possible use of mifepristone for painful fibroids

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

8 Mar 2011

New insight into multiple sclerosis

Scientists have blocked harmful immune cells from entering the brain in mice with a condition similar to multiple sclerosis.

8 Mar 2011

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics, said the company had been granted a US patent for Sym004 as well as other antibody compositions containing at least two distinct anti-EGFR antibodies having certain binding characteristics.

7 Mar 2011

Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

The U.S. Food and Drug Administration today announced that monthly liver enzyme tests are no longer required for those taking Letairis tablets (ambrisentan), used to treat high blood pressure in the vessels that carry blood to the lungs (pulmonary arterial hypertension, or PAH).

5 Mar 2011

Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in the Journal of the American Society of Nephrology. The published study results suggest that atrasentan, used in conjunction with renin-angiotensin system inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes.

5 Mar 2011

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

Sangamo BioSciences, Inc. announced that data from its programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections, held in Boston from February 27 to March 2, 2011.

4 Mar 2011

New promising detection technology identifies cancer cells early

Yesterday's Wall Street Journal (March 1) published a lead article on page D1 entitled "Researchers Create Better Ways To Spot Cancer Cells", which described the research by Dr. Edward R. Flynn, of Senior Scientific LLC. The article was authored by Shirley S. Wang.

4 Mar 2011

Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

Palatin Technologies, Inc. today announced that the U.S. Food and Drug Administration has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma.

4 Mar 2011

Receptor News and Research

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Novartis new MS treatment receives Notice of Compliance in Canada

Idera reports $6.0 million net loss for fourth quarter 2010

Despite aspirin therapy, specific inflammatory pathways may influence risk of colorectal cancer

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Swine flu virus may evolve into a deadlier form

Blood biomarker may help decide intake of aspirin or NSAIDs for reduction of cancer risk

Immunologists identify key cell component that triggers allergic responses to cat dander

Study supports DNA mismatch repair test for bowel cancer

Multiple target therapy may treat HER2-positive breast cancers

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Researchers elucidate how sensory, motor fibers interact at molecular level to form nerves

URMC research confirms possible use of mifepristone for painful fibroids

New insight into multiple sclerosis

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

Monthly liver enzyme tests not required for PAH patients taking Letairis tablets: FDA

Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

Sangamo's preclinical ZFN-gene modification studies for HIV/AIDS treatment presented at CROI

New promising detection technology identifies cancer cells early

Palatin receives FDA clearance to begin PL-3994 Phase 2A trial for asthma treatment

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News